Ovid Therapeutics is continuing a clinical research study called NEPTUNE. The NEPTUNE study will evaluate the safety and effectiveness of an investigational medicine called OV101 on various aspects associated with Angelman syndrome in individuals age 2 – 12 years old.
Criteria and Expectations
- Participant must be 2-12 years old and have a confirmed diagnosis of Angelman syndrome
- Participant must have fewer than 3 seizures lasting less than 3 minutes weekly
- The primary caregiver for the individual with Angelman syndrome will need to be able to complete study activities and answer some questions from the study doctor at prescheduled times.
- The study will last approximately four months and include phone appointments and four in-person visits to the medical center or study site conducting the study.